This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Chemo Espana S.L. Acquired Indonesian based PT Nufarindo

Jakarta, December 11, 2012 — Chemo Espana S.L. today announced that it has completed the acquisition of 75% of PT Nufarindo. This transaction will give Chemo a platform to grow in Indonesia with an established company and brand as well as allow it to bring its own patented products into the Indonesian market.

PT Nufarindo, headquartered in Semarang, Central Java is a local pharmaceutical manufacture with a wide portfolio of established products selling both prescription and OTC markets.

Commenting on the transaction Mr. Alberto Eduardo Surijon, MD Asia-Pacific Chemo, says, "Chemo is pleased to be given the opportunity to acquire control of Nufarindo. Through the acquisition, Chemo will aim to develop a position among the leading foreign pharmaceutical companies by 2017, focusing on the current portfolio of off-patent branded products as well as innovative products that are planned to be introduced to the market during the next couple of years. As a global leader in Women's Health, Chemo plans to introduce a wide range of products in this therapeutic area as well as other strategic focus areas such as Respiratory and CNS. Chemo is committed to further invest significantly in the existing site as well as people. Beside the positive outlook in Indonesia itself, the acquisition is also expected to be beneficial for other markets in the region, as Nufarindo's modern manufacturing facilities can likely be leveraged by other countries in the SEA region."

Contacts

Name:
Butty Lumbantoruan
Company:
Deloitte Indonesia
Job Title:
Marketing Communications Director
Phone:
Email
iddttl@deloitte.com